Top ▲

Guanylyl cyclase, α2β1

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 2897

Nomenclature: Guanylyl cyclase, α2β1

Abbreviated Name: GC-2

Family: Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase

Contents:

Quaternary Structure: Subunits
Guanylyl cyclase α2 subunit
Guanylyl cyclase β1 subunit
Previous and Unofficial Names Click here for help
NOGCR α2β1 | sGC | Soluble guanylyl cyclase
Database Links Click here for help
BRENDA 4.6.1.2
KEGG Enzyme 4.6.1.2
Enzyme Reaction Click here for help
EC Number: 4.6.1.2
Endogenous ligand(s)
NO

Download all structure-activity data for this target as a CSV file go icon to follow link

Activators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
cinaciguat Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Activation - - 7
⤷ [Binds to: apo-GC-2] [7]
riociguat Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Activation - - 5-6
⤷ [5-6]
YC-1 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Activation - - 3-4
⤷ [3-4]
vericiguat Small molecule or natural product Approved drug Click here for species-specific activity table Hs Activation - - 2
⤷ [2]
olinciguat Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Activation - - 1
⤷ [1]
Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
ODQ Small molecule or natural product Click here for species-specific activity table Hs Inhibition - -
⤷

References

Show »

1. Buys ES, Zimmer DP, Chickering J, Graul R, Chien YT, Profy A, Hadcock JR, Masferrer JL, Milne GT. (2018) Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential. Nitric Oxide, 78: 72-80. [PMID:29859918]

2. Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM et al.. (2017) Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. J Med Chem, 60 (12): 5146-5161. [PMID:28557445]

3. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. (1994) YC-1, a novel activator of platelet guanylate cyclase. Blood, 84 (12): 4226-33. [PMID:7527671]

4. Russwurm M, Behrends S, Harteneck C, Koesling D. (1998) Functional properties of a naturally occurring isoform of soluble guanylyl cyclase. Biochem J, 335 ( Pt 1): 125-30. [PMID:9742221]

5. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U et al.. (2001) NO-independent regulatory site on soluble guanylate cyclase. Nature, 410 (6825): 212-5. [PMID:11242081]

6. Stasch JP, Hobbs AJ. (2009) NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol, (191): 277-308. [PMID:19089334]

7. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U et al.. (2002) NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol, 136 (5): 773-83. [PMID:12086987]

How to cite this page